Approccio diagnostico-terapeutico al ritardo di crescita intrauterino

Translated title of the contribution: Intrauterine growth retardation: Diagnostic and therapeutic approach

A. Di Cesare Merlone, E. Bozzola, R. M. Cerbo, G. Rondini

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Intrauterine growth retardation (IUGR) refers to the fetal growth pattern and assumes that at least 2 intrauterine growth assessments are performed, indicating a low growth velocity in the fetus. The term "small for gestational age" (SGA) does not refer to fetal growth but to the size of the infant at birth. Infants with SGA have a low weight and/or length for their gestational age at birth below the 10th percentile or -2 SD. Approximately 3-5% of all newborns are born SGA. The etiology of SGA/IUGR is not known. The majority (80-85%) of infants born SGA catch-up within the normal range by 2 years of age. SGA has also been associated with increased prevalence of hypertension and dyslipidaemia at a relatively young age. Most controlled trials have shown a beneficial effect of GH treatment. The growth response seems to be due to the cumulative dose received, parenteral adjusted height standard deviation score (SDS) and bone age pretreatment, baseline overnight peak of GH and IGF-I levels. During GH treatment, children born SGA show a significant increase in fasting levels of insulin and proinsulin and a decrease in insulin sensitivity. Fasting glucose levels significantly increase. All these effects are reversible upon interruption of treatment. However, fasting insulin concentrations as well as glucosylated hemoglobin must be carefully monitored during GH treatment. Total cholesterol, LDL cholesterol and the atherogenic index significantly decrease during GH treatment. An acceleration of bone maturation with GH treatment has been reported even though a gain in heigth SDS for bone age is demonstrated.

Original languageItalian
Pages (from-to)183-188
Number of pages6
JournalMinerva Pediatrica
Volume56
Issue number2
Publication statusPublished - Apr 2004

Fingerprint

Fetal Growth Retardation
Gestational Age
Small for Gestational Age Infant
Fasting
Fetal Development
Bone and Bones
Therapeutics
Growth
Parturition
Insulin
Proinsulin
Dyslipidemias
Insulin-Like Growth Factor I
LDL Cholesterol
Insulin Resistance
Reference Values
Hemoglobins
Fetus
Cholesterol
Newborn Infant

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Approccio diagnostico-terapeutico al ritardo di crescita intrauterino. / Di Cesare Merlone, A.; Bozzola, E.; Cerbo, R. M.; Rondini, G.

In: Minerva Pediatrica, Vol. 56, No. 2, 04.2004, p. 183-188.

Research output: Contribution to journalArticle

Di Cesare Merlone, A, Bozzola, E, Cerbo, RM & Rondini, G 2004, 'Approccio diagnostico-terapeutico al ritardo di crescita intrauterino', Minerva Pediatrica, vol. 56, no. 2, pp. 183-188.
Di Cesare Merlone, A. ; Bozzola, E. ; Cerbo, R. M. ; Rondini, G. / Approccio diagnostico-terapeutico al ritardo di crescita intrauterino. In: Minerva Pediatrica. 2004 ; Vol. 56, No. 2. pp. 183-188.
@article{9cfea7a14a2a49dba5bc84ea2b7197fb,
title = "Approccio diagnostico-terapeutico al ritardo di crescita intrauterino",
abstract = "Intrauterine growth retardation (IUGR) refers to the fetal growth pattern and assumes that at least 2 intrauterine growth assessments are performed, indicating a low growth velocity in the fetus. The term {"}small for gestational age{"} (SGA) does not refer to fetal growth but to the size of the infant at birth. Infants with SGA have a low weight and/or length for their gestational age at birth below the 10th percentile or -2 SD. Approximately 3-5{\%} of all newborns are born SGA. The etiology of SGA/IUGR is not known. The majority (80-85{\%}) of infants born SGA catch-up within the normal range by 2 years of age. SGA has also been associated with increased prevalence of hypertension and dyslipidaemia at a relatively young age. Most controlled trials have shown a beneficial effect of GH treatment. The growth response seems to be due to the cumulative dose received, parenteral adjusted height standard deviation score (SDS) and bone age pretreatment, baseline overnight peak of GH and IGF-I levels. During GH treatment, children born SGA show a significant increase in fasting levels of insulin and proinsulin and a decrease in insulin sensitivity. Fasting glucose levels significantly increase. All these effects are reversible upon interruption of treatment. However, fasting insulin concentrations as well as glucosylated hemoglobin must be carefully monitored during GH treatment. Total cholesterol, LDL cholesterol and the atherogenic index significantly decrease during GH treatment. An acceleration of bone maturation with GH treatment has been reported even though a gain in heigth SDS for bone age is demonstrated.",
keywords = "Fetal growth retardation, diagnosis, Fetal growth retardation, etiology, Fetal growth retardation, therapy",
author = "{Di Cesare Merlone}, A. and E. Bozzola and Cerbo, {R. M.} and G. Rondini",
year = "2004",
month = "4",
language = "Italian",
volume = "56",
pages = "183--188",
journal = "Minerva Pediatrica",
issn = "0026-4946",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "2",

}

TY - JOUR

T1 - Approccio diagnostico-terapeutico al ritardo di crescita intrauterino

AU - Di Cesare Merlone, A.

AU - Bozzola, E.

AU - Cerbo, R. M.

AU - Rondini, G.

PY - 2004/4

Y1 - 2004/4

N2 - Intrauterine growth retardation (IUGR) refers to the fetal growth pattern and assumes that at least 2 intrauterine growth assessments are performed, indicating a low growth velocity in the fetus. The term "small for gestational age" (SGA) does not refer to fetal growth but to the size of the infant at birth. Infants with SGA have a low weight and/or length for their gestational age at birth below the 10th percentile or -2 SD. Approximately 3-5% of all newborns are born SGA. The etiology of SGA/IUGR is not known. The majority (80-85%) of infants born SGA catch-up within the normal range by 2 years of age. SGA has also been associated with increased prevalence of hypertension and dyslipidaemia at a relatively young age. Most controlled trials have shown a beneficial effect of GH treatment. The growth response seems to be due to the cumulative dose received, parenteral adjusted height standard deviation score (SDS) and bone age pretreatment, baseline overnight peak of GH and IGF-I levels. During GH treatment, children born SGA show a significant increase in fasting levels of insulin and proinsulin and a decrease in insulin sensitivity. Fasting glucose levels significantly increase. All these effects are reversible upon interruption of treatment. However, fasting insulin concentrations as well as glucosylated hemoglobin must be carefully monitored during GH treatment. Total cholesterol, LDL cholesterol and the atherogenic index significantly decrease during GH treatment. An acceleration of bone maturation with GH treatment has been reported even though a gain in heigth SDS for bone age is demonstrated.

AB - Intrauterine growth retardation (IUGR) refers to the fetal growth pattern and assumes that at least 2 intrauterine growth assessments are performed, indicating a low growth velocity in the fetus. The term "small for gestational age" (SGA) does not refer to fetal growth but to the size of the infant at birth. Infants with SGA have a low weight and/or length for their gestational age at birth below the 10th percentile or -2 SD. Approximately 3-5% of all newborns are born SGA. The etiology of SGA/IUGR is not known. The majority (80-85%) of infants born SGA catch-up within the normal range by 2 years of age. SGA has also been associated with increased prevalence of hypertension and dyslipidaemia at a relatively young age. Most controlled trials have shown a beneficial effect of GH treatment. The growth response seems to be due to the cumulative dose received, parenteral adjusted height standard deviation score (SDS) and bone age pretreatment, baseline overnight peak of GH and IGF-I levels. During GH treatment, children born SGA show a significant increase in fasting levels of insulin and proinsulin and a decrease in insulin sensitivity. Fasting glucose levels significantly increase. All these effects are reversible upon interruption of treatment. However, fasting insulin concentrations as well as glucosylated hemoglobin must be carefully monitored during GH treatment. Total cholesterol, LDL cholesterol and the atherogenic index significantly decrease during GH treatment. An acceleration of bone maturation with GH treatment has been reported even though a gain in heigth SDS for bone age is demonstrated.

KW - Fetal growth retardation, diagnosis

KW - Fetal growth retardation, etiology

KW - Fetal growth retardation, therapy

UR - http://www.scopus.com/inward/record.url?scp=3042691764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042691764&partnerID=8YFLogxK

M3 - Articolo

C2 - 15249902

AN - SCOPUS:3042691764

VL - 56

SP - 183

EP - 188

JO - Minerva Pediatrica

JF - Minerva Pediatrica

SN - 0026-4946

IS - 2

ER -